Coordinated Implementation of Chikungunya Virus Reverse Transcription–PCR
Marcus Panning, Remi N. Charrel, Oliver D. Mantke, Olfert Landt, Matthias Niedrig, and Christian Drosten
Author affiliations: Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (M. Panning); Université de la Méditerranée, Marseille, France (R.N. Charrel); Robert Koch Institute, Berlin, Germany (O.D. Mantke, M. Niedrig); TIB MOLBIOL, Berlin (O. Landt); University of Bonn Medical Centre, Bonn, Germany (C. Drosten)
Figure. Probit analysis of laboratories with a positive result (y axes) for chikungunya virus in relation to viral RNA concentration in positive samples (x axes). A) Laboratories using in-house reverse transcription–PCRs (RT-PCRs) (n = 18) had a 50% certainty of having a positive result at 10,000 RNA copies/mL (95% confidence interval [CI] 3,162–19,952). B) Laboratories using a preformulated RT-PCR (n = 13) had a 50% certainty of having a positive result at 1,288 RNA copies/mL (95% CI 416–2,344). Data points represent individual samples in the test panel. Thick line is the regression line calculated on the basis of a probit model (dose-response curve), and thin lines are 95% CIs. Data fit into the model with p<0.00001.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.